ESMO 2018 | CAR T-cell therapy: CRS and adverse effects
Michel Sadelain
• 22 Jan 2019
Cytokine release syndrome (CRS) has been a prominent issue for CAR T-cell therapy. Here, Michel Sadelain, MD, PhD, of the Memorial Sloan Kettering Cancer Center, New York, NY, explains how CRS was first identified, its biology and its current management, while still calling for novel interventions to prevent its occurrence. This video was recorded at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany.
